These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1579 related articles for article (PubMed ID: 30885690)
1. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance. Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M Front Immunol; 2021; 12():799455. PubMed ID: 35069581 [TBL] [Abstract][Full Text] [Related]
3. Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy. Su X; Li J; Xu X; Ye Y; Wang C; Pang G; Liu W; Liu A; Zhao C; Hao X J Transl Med; 2024 Aug; 22(1):751. PubMed ID: 39123227 [TBL] [Abstract][Full Text] [Related]
4. Immune-Checkpoint Blockade Therapy in Lymphoma. Kuzume A; Chi S; Yamauchi N; Minami Y Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751706 [TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034 [TBL] [Abstract][Full Text] [Related]
6. Treg-mediated acquired resistance to immune checkpoint inhibitors. Saleh R; Elkord E Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738 [TBL] [Abstract][Full Text] [Related]
7. Understanding genetic determinants of resistance to immune checkpoint blockers. Aspeslagh S; Chabanon RM; Champiat S; Postel-Vinay S Semin Cancer Biol; 2020 Oct; 65():123-139. PubMed ID: 31881338 [TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Hargadon KM; Johnson CE; Williams CJ Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692 [TBL] [Abstract][Full Text] [Related]
9. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker. Wang Z; Wu X Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727 [TBL] [Abstract][Full Text] [Related]
10. Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors. Berland L; Gabr Z; Chang M; Ilié M; Hofman V; Rignol G; Ghiringhelli F; Mograbi B; Rashidian M; Hofman P Front Immunol; 2024; 15():1384121. PubMed ID: 38903504 [TBL] [Abstract][Full Text] [Related]
11. Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies. Liao L; Xu H; Zhao Y; Zheng X Front Med; 2023 Oct; 17(5):805-822. PubMed ID: 37897562 [TBL] [Abstract][Full Text] [Related]
12. Immunotherapy and predictive immunologic profile: the tip of the iceberg. Cunha Pereira T; Rodrigues-Santos P; Almeida JS; Rêgo Salgueiro F; Monteiro AR; Macedo F; Soares RF; Domingues I; Jacinto P; Sousa G Med Oncol; 2021 Mar; 38(5):51. PubMed ID: 33788049 [TBL] [Abstract][Full Text] [Related]
13. Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination. De Guillebon E; Dardenne A; Saldmann A; Séguier S; Tran T; Paolini L; Lebbe C; Tartour E Int J Cancer; 2020 Sep; 147(6):1509-1518. PubMed ID: 31997345 [TBL] [Abstract][Full Text] [Related]
14. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy. Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476 [TBL] [Abstract][Full Text] [Related]
15. Clinical Challenges of Immune Checkpoint Inhibitors. de Miguel M; Calvo E Cancer Cell; 2020 Sep; 38(3):326-333. PubMed ID: 32750319 [TBL] [Abstract][Full Text] [Related]
16. Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors. Huang T; Li F; Cheng X; Wang J; Zhang W; Zhang B; Tang Y; Li Q; Zhou C; Tu S Front Immunol; 2021; 12():619209. PubMed ID: 33790893 [TBL] [Abstract][Full Text] [Related]
17. Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC. Olaoba OT; Ligali FC; Alabi ZO; Akinyemi AO; Ayinde KS Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188483. PubMed ID: 33232723 [TBL] [Abstract][Full Text] [Related]
18. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer. Zeng Z; Yang B; Liao Z Future Oncol; 2021 Apr; 17(12):1553-1569. PubMed ID: 33397136 [TBL] [Abstract][Full Text] [Related]
19. What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy? Wang Q; Xie B; Liu S; Shi Y; Tao Y; Xiao D; Wang W Front Immunol; 2021; 12():773168. PubMed ID: 35003090 [TBL] [Abstract][Full Text] [Related]
20. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B Front Immunol; 2020; 11():1956. PubMed ID: 32983126 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]